Autonomix Medical (AMIX) Registration filing summary

Company overview and business model

• Development-stage medical device company focused on a catheter-based platform for sensing and treating nervous system disorders, initially targeting pain in pancreatic cancer patients.

• Proprietary technology enables high-sensitivity neural signal detection and real-time processing via a microchip embedded in the catheter.

• Product strategy integrates diagnostic sensing and therapeutic RF ablation, with plans to expand indications to chronic pain, hypertension, cardiovascular disease, and other nerve-related disorders.

• Initial clinical focus is on minimally invasive pain management for oncology and gastroenterology, with future expansion into broader applications.

• Revenue model centers on single-use disposable catheters for hospital labs, with additional potential as a standalone sensing technology or combined system.

Financial performance and metrics

• As of June 30, 2025: $8.6 million in cash, $7.0 million in working capital, and an accumulated deficit of $53.7 million.

• Fiscal year ended March 31, 2025: net loss of $11.4 million, operating expenses of $11.6 million, and no revenue generated.

• Research and development expenses increased 112% year-over-year to $4.7 million, driven by clinical trial and product development costs.

• General and administrative expenses rose 31% to $6.9 million, mainly due to compensation, stock-based compensation, and professional fees.

• Company estimates current cash resources will fund operations into the second quarter of 2026; additional $32–$40 million needed to reach commercialization.

Use of proceeds and capital allocation

• May receive up to $15.0 million in gross proceeds from sales of common stock to Lincoln Park Capital Fund under a committed equity facility.

• Proceeds will be used for working capital and general corporate purposes, including research and development and clinical trial advancement.

• Management has broad discretion over use of proceeds, with investments expected in clinical, regulatory, and product development activities.